Active Recombinant Human CTLA4 Protein, His-Tagged

• Cat.No.: CTLA4-01H
• Product Overview: Recombinant Human CTLA4 Protein, His-Tagged was expressed in Baculovirus cell

Specification

• Description: This gene is a member of the immunoglobulin superfamily and encodes a protein which transmits an inhibitory signal to T cells. The protein contains a V domain, a transmembrane domain, and a cytoplasmic tail. Alternate transcriptional splice variants, encoding different isoforms, have been characterized. The membrane-bound isoform functions as a homodimer interconnected by a disulfide bond, while the soluble isoform functions as a monomer. Mutations in this gene have been associated with insulin-dependent diabetes mellitus, Graves disease, Hashimoto thyroiditis, celiac disease, systemic lupus erythematosus, thyroid-associated orbitopathy, and other autoimmune diseases.
• Source: Baculovirus
• Species: Human
• Tag: His
• Form: Liquid
• Bio-activity: The activity is determined by the IL-2 ELISA in a using Jurkat human acute T cell leukemia cells. The ED50 range ≤150ng/ml with Human B7 1/CD80.
• Molecular Mass: 40.8 kDa (368aa)
• Endotoxin: < 1 EU per 1ug of protein (determined by LAL method)
• Purity: > 95% by SDS-PAGE
• Applications: SDS-PAGE, Bioactivity
• Storage: Can be stored at +2C to +8C for 1 week. For long term storage, aliquot and store at -20C to -80C. Avoid repeated freezing and thawing cycles.
• Concentration: 0.5mg/ml (determined by absorbance at 280nm)
• Storage Buffer: Liquid in. Phosphate-Buffered Saline (pH 7.4) containing 10% glycerol

Gene Information

• Gene Name: CTLA4 cytotoxic T-lymphocyte associated protein 4 [ Homo sapiens (human) ]
• Official Symbol: CTLA4
• Synonyms: Cytotoxic T-lymphocyte protein 4, Cytotoxic T-lymphocyte-associated antigen 4, CTLA4, ALPS5, CD, CD152, CELIAC3, CTLA-4, GRD4, GSE, IDDM12, ATGP3364
• Gene ID: 1493
• mRNA Refseq: NM_001037631.3
• Protein Refseq: NP_001032720.1
• MIM: 123890
• UniProt ID: P16410

Reviews

04/17/2019

It has become an indispensable tool in my experiments, consistently meeting my needs and providing valuable insights.

11/25/2018

The CTLA4 protein is a top-quality product that is sure to fulfill my experimental requirements.

01/28/2017

the ease of use and compatibility of the CTLA4 protein with various techniques further enhances its appeal.

Q&As

Are there ongoing clinical trials exploring CTLA-4 inhibitors in combination with other immunotherapies?

Yes, several clinical trials are investigating the combination of CTLA-4 inhibitors with PD-1 inhibitors and other immunotherapies to improve the overall effectiveness of cancer treatment.

How does the expression of CTLA-4 vary in different types of immune cells?

CTLA-4 is expressed on various immune cells, including T cells, regulatory T cells (Tregs), and some B cells, contributing to its diverse immunoregulatory functions.

In what ways can CTLA-4 be utilized in organ transplantation?

Modulating CTLA-4 may have applications in organ transplantation by suppressing the immune response against transplanted tissues and reducing the risk of rejection.

How does CTLA-4 contribute to the maintenance of immune tolerance?

CTLA-4 is involved in the suppression of autoreactive T cells, contributing to the prevention of autoimmune responses by maintaining immune tolerance.

How does CTLA-4 blockade differ from PD-1/PD-L1 blockade in cancer immunotherapy?

While both CTLA-4 and PD-1/PD-L1 inhibitors enhance anti-tumor immune responses, they target different checkpoints in the immune system. CTLA-4 primarily regulates T-cell activation in the early stages, whereas PD-1/PD-L1 acts later in the immune response.